ZIXXIVUS
LIVE

Serial Number

98139376

Owner

Vanda Pharmaceuticals Inc.

Attorney

Jayme M. Torelli

Filing Date

Aug 18, 2023

Add to watchlist:

No watchlists yet
View on USPTO

ZIXXIVUS Trademark

Serial Number: 98139376

ZIXXIVUS is a trademark filed by Vanda Pharmaceuticals Inc. on August 18, 2023. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

Vanda Pharmaceuticals Inc. (104 trademarks)

Suite 300
Rockville, MD 20850

Entity Type: 03

Trademark Details

Filing Date

August 18, 2023

Registration Date

Not Registered

Published for Opposition

December 19, 2023

Goods & Services

Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations for the central nervous system; Pharmaceutical preparations for the prevention of motion sickness; Pharmaceutical preparations for the prevention of social anxiety or performance anxiety; Pharmaceutical preparations for the treatment and prevention of craving; Pharmaceutical preparations for the treatment and prevention of motion sickness; Pharmaceutical preparations for the treatment and prevention of insomnia; Pharmaceutical preparations for the treatment and prevention of social anxiety or performance anxiety; Pharmaceutical preparations for the treatment of circadian rhythm diseases and disorders; Pharmaceutical preparations for the treatment of Non-24-Hour Sleep-Wake Disorder; Pharmaceutical preparations for the treatment of jet lag disorder; Pharmaceutical preparations for the treatment of Delayed Sleep Phase Disorder (DSPD); Pharmaceutical preparations for the treatment of bipolar disorder; Pharmaceutical preparations for the treatment of schizophrenia; Pharmaceutical preparations for the treatment of atopic dermatitis; Pharmaceutical preparations for the treatment of pruritus; Pharmaceutical preparations for the treatment of gastroparesis; Pharmaceutical preparations for the treatment of motion sickness; Pharmaceutical preparations for the treatment of hematologic malignancies; Pharmaceutical preparations for the treatment of insomnia; Pharmaceutical preparations for the treatment of Autism Spectrum Disorder (ASD); Pharmaceutical preparations for the treatment of Parkinson's Disease Psychosis; Pharmaceutical preparations for the treatment of COVID-19 pneumonia; Pharmaceutical preparations for the treatment of social anxiety or performance anxiety; Pharmaceutical preparations for the treatment of Smith-Magenis Syndrome; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in dermatology

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 29, 2026 EXRA
SOU EXTENSION 4 GRANTED
Jan 28, 2026 EX4G
SOU EXTENSION 4 FILED
Jan 28, 2026 EXT4
SOU TEAS EXTENSION RECEIVED
Jan 28, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 28, 2025 EXRA
SOU EXTENSION 3 GRANTED
Jun 27, 2025 EX3G
SOU EXTENSION 3 FILED
Jun 27, 2025 EXT3
SOU TEAS EXTENSION RECEIVED
Jun 27, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 4, 2025 EXRA
SOU EXTENSION 2 GRANTED
Jan 3, 2025 EX2G
SOU EXTENSION 2 FILED
Jan 3, 2025 EXT2
SOU TEAS EXTENSION RECEIVED
Jan 2, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 17, 2024 EXRA
SOU EXTENSION 1 GRANTED
Jun 17, 2024 EX1G
SOU EXTENSION 1 FILED
Jun 17, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
Jun 17, 2024 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Feb 13, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 19, 2023 NPUB
PUBLISHED FOR OPPOSITION
Dec 19, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 29, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 16, 2023 CNSA
ASSIGNED TO EXAMINER
Nov 13, 2023 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 18, 2023 NWOS
NEW APPLICATION ENTERED
Aug 22, 2023 NWAP